A5036950995- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- CNS Lymphoma Diagnosis and Treatment
- Virus-based gene therapy research
- Monoclonal and Polyclonal Antibodies Research
- Molecular Biology Techniques and Applications
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Neuroscience and Neuropharmacology Research
- Cutaneous lymphoproliferative disorders research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Chemotherapy-induced cardiotoxicity and mitigation
- Neutropenia and Cancer Infections
- Palliative Care and End-of-Life Issues
- T-cell and Retrovirus Studies
- Salivary Gland Disorders and Functions
- Biosimilars and Bioanalytical Methods
- Nicotinic Acetylcholine Receptors Study
- Vascular Tumors and Angiosarcomas
Charles University
2014-2025
General University Hospital in Prague
2017-2024
Czech Academy of Sciences
2018
Hypertension Institute
2018
Czech Academy of Sciences, Institute of Physiology
2018
Karolinska University Hospital
2011
Karolinska Institutet
2011
Comenius University Bratislava
2010
Symptoms of lymphomas include peripheral lymphadenopathy, B-symptoms, and other organ-specific symptoms; however, data on initial symptoms incidence in diffuse large B-cell lymphoma (DLBCL) remain limited. We aimed to investigate real-world patterns DLBCL symptoms, correlating them with baseline characteristics symptom onset-to-diagnosis interval. Patients diagnosed between 2010 2021 receiving R-CHOP were screened. 706 individuals reported analyzed. 682 (97%) patients had documented...
Ligands of auxiliary α 2 δ subunit voltage-dependent calcium channels (VDCCs) decrease elevated L-type VDCCs surface expression in arterial myocytes and constriction spontaneously hypertensive rats (SHR). However, their effect on blood pressure (BP) is unclear. In this study, we investigated the hemodynamic response to acute chronic administration gabapentin, a ligand VDCCs, adult SHR with established neurogenic hypertension. The gabapentin lowered BP heart rate more conscious than...
Altered calcium sensitization (mediated by RhoA/Rho-kinase pathway) and enhanced entry through L-type voltage-dependent channels (L-VDCCs) participate in blood pressure (BP) maintenance of adult spontaneously hypertensive rats (SHRs). This study aimed to evaluate ontogenetic changes these two pathways BP control SHR Wistar-Kyoto (WKY) aged 3, 5, 7, 13, 26 42 weeks.BP response acute administration Rho-kinase inhibitor fasudil or L-VDCC blocker nifedipine the expression particular components...
Introduction Significant proportion of patients with diffuse large B-cell lymphoma (DLBCL) is refractory or relapse (R/R) after the treatment. The prognosis this patient cohort remains poor. Novel strategies mainly based on immunotherapy and targeted agents are currently being studied. Glofitamab novel T-cell-engaging bispecific antibody possessing a 2:1 structure bivalent CD20 binding. Its safety efficacy in R/R non-Hodgkin including DLBCL were evaluated phase I-II NP30179 trial.
Tisagenlecleucel (tisa-cel) is a CD19 - specific CAR-T cell product approved for the treatment of relapsed/refractory (r/r) DLBCL or B-ALL. We have followed group patients diagnosed with childhood B-ALL ( n = 5), adult 2), and 25) who were treated tisa-cel under non-clinical trial conditions. The goal was to determine how intensive pretreatment affects produced cells, their in vivo expansion, outcome therapy. Multiparametric flow cytometry used analyze material manufacturing cells...
Urinary tract infections (UTI) are one of the most common infectious diseases worldwide. The majority is caused by uropathogenic Escherichia coli. Emerging resistances against conventional antimicrobial therapy requires novel treatment strategies. Beside its role in erythropoiesis, erythropoietin has been recognized to exert tissue-protective and immunomodulatory properties. Here, we investigated nonerythropoietic analogue ARA290 for potential properties modulate uroepithelial infection E....
Cutaneous T-cell lymphomas (CTCL) represent rare non-Hodgkin (NHL) with an incidence less than 1 per 100,000 inhabitants. The most common type of CTCL is mycosis fungoides (MF), which represents approximately 60% all CTCL, followed by Sézary syndrome (SS), 5%. We retrospectively analyzed the outcome 118 patients MF (n=96) and SS (n=22) treated between years 1998 2021 at Charles University General Hospital in Prague, Czech Republic. ratio men women was 1.2:1 (62 men, 56 women). median age...
Azacitidine (AZA) for higher risk MDS patients is a standard therapy with limited durability. To monitor mutation dynamics during AZA we utilized massive parallel sequencing of 54 genes previously associated MDS/AML pathogenesis. Serial sampling before and 38 (reaching median overall survival 24 months (Mo) 60% clinical responses) identified 116 somatic pathogenic variants allele frequency (VAF) exceeding 5%. High accuracy data was achieved via duplicate libraries from myeloid cells T-cell...
Introduction: Primary mediastinal B-cell lymphoma (PMBL) has specific clinical and biological characteristics. The current standard of therapy is based on immunochemotherapy which means rituximab anthracycline chemotherapy (R-CHT), either CHOP, CHOEP or DA-EPOCH more intensive chemotherapy. Radiotherapy (RT) consolidation been a especially in pre PET era. Although the RT started to be skipped now situation complete metabolic response after R-CHT, there lack data answer this question....
T-lymfocyty s chimérickým antigenním receptorem jsou v terapii refrakterních či relabovaných B-non-Hodgkinských lymfomů České republice využívány již několik let. V kontextu dostupných dat se jejich využití rozšiřuje - jak ve smyslu indikovaných diagnóz, tak přesunu do časnějších terapeutických linií. Některé produkty mají ČR schválené použití i 2. léčebné linii difuzního velkobuněčného lymfomu; objevují data pro první linii. Spektrum u kterých tato terapie využívá, dále zahrnuje primární...
Abstract Aim The aim of this study was to analyse the outcomes patients with large B‐cell lymphoma (LBCL) treated chimeric antigen receptor T‐cell therapy (CAR‐Tx), a focus on after CAR failure, and define risk factors for rapid progression further treatment. Methods We analysed 107 LBCL from Czech Republic Slovakia who were in ≥3rd‐line tisagenlecleucel or axicabtagene ciloleucel between 2019 2022. Results overall response rate (ORR) 60%, 50% complete (CR) rate. median progression‐free...